Reports Q2 revenue $33.5M, consensus $31.0M. “Our team has made great progress positioning Harrow as a top-tier U.S.-focused ophthalmic pharmaceutical company,” said Mark L. Baum, CEO of Harrow. “Since January of 2023, through a series of transactions, we have not only improved Harrow’s balance sheet, but we’ve dramatically improved Harrow’s product portfolio, which is now one of the most comprehensive ophthalmic pharmaceutical offerings in the U.S. market. With what we now have in our “bag” and continued execution and operational performance by the Harrow team, we believe we are on our way to achieving the highest financial goals for Harrow’s stockholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HROW:
- HROW Upcoming Earnings Report: What to Expect?
- Harrow Health 3.38M share Spot Secondary priced at $17.75
- Harrow Health signs agreement to acquire certain comercial rights from Santen
- Harrow Health sees Q2 revenue in excess of $31M, consensus $29.2M
- Harrow Health files to sell common stock, no amount given